APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026188 pages

Choose your research edition.

Industry ResearchHuman Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) include Weiguang Biological, CTBB, Shanghai RAAS, Nanyue Biopharming, Hualan Bio, Sinopharm, Guangdong Shuagnlin Bio-pharmacy, Boya-Bio and Beijing Tiantan Biological Products, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Company

Weiguang Biological

CTBB

Shanghai RAAS

Nanyue Biopharming

Hualan Bio

Sinopharm

Guangdong Shuagnlin Bio-pharmacy

Boya-Bio

Beijing Tiantan Biological Products

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Type

1.25g/25ml

10g/200ml

1g/20ml

2.5g/50ml

5g/100ml

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Application

Hospital

Clinic

Others

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends Table 2. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers Table 3. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges Table 4. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints Table 5. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Manufacturers Table 9. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers, Product Type & Application Table 13. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 1.25g/25ml Table 17. Major Manufacturers of 10g/200ml Table 18. Major Manufacturers of 1g/20ml Table 19. Major Manufacturers of 2.5g/50ml Table 20. Major Manufacturers of 5g/100ml Table 21. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 23. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 24. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2026) Table 25. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2027-2032) Table 26. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (K Units) Table 28. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (K Units) Table 29. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2026) Table 30. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 36. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 37. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2026) Table 38. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2027-2032) Table 39. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (K Units) Table 41. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (K Units) Table 42. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2026) Table 43. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2027-2032) Table 44. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026) & (K Units) Table 46. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2021-2026) Table 47. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 51. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 52. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 54. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 61. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2021-2026) Table 65. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2027-2032) Table 66. Weiguang Biological Company Information Table 67. Weiguang Biological Business Overview Table 68. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 70. Weiguang Biological Recent Development Table 71. CTBB Company Information Table 72. CTBB Business Overview Table 73. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 75. CTBB Recent Development Table 76. Shanghai RAAS Company Information Table 77. Shanghai RAAS Business Overview Table 78. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 80. Shanghai RAAS Recent Development Table 81. Nanyue Biopharming Company Information Table 82. Nanyue Biopharming Business Overview Table 83. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 85. Nanyue Biopharming Recent Development Table 86. Hualan Bio Company Information Table 87. Hualan Bio Business Overview Table 88. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 90. Hualan Bio Recent Development Table 91. Sinopharm Company Information Table 92. Sinopharm Business Overview Table 93. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 95. Sinopharm Recent Development Table 96. Guangdong Shuagnlin Bio-pharmacy Company Information Table 97. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 98. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 100. Guangdong Shuagnlin Bio-pharmacy Recent Development Table 101. Boya-Bio Company Information Table 102. Boya-Bio Business Overview Table 103. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 105. Boya-Bio Recent Development Table 106. Beijing Tiantan Biological Products Company Information Table 107. Beijing Tiantan Biological Products Business Overview Table 108. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 110. Beijing Tiantan Biological Products Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors List Table 114. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Image Figure 2. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (2021-2032) & (K Units) Figure 5. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 1.25g/25ml Image Figure 9. 10g/200ml Image Figure 10. 1g/20ml Image Figure 11. 2.5g/50ml Image Figure 12. 5g/100ml Image Figure 13. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2032) Figure 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2032) Figure 25. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2032) Figure 28. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 30. U.S. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 35. Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 42. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 50. Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Figure 61. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Figure 63. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • 1.25g/25ml
  • 10g/200ml
  • 1g/20ml
  • 2.5g/50ml
  • 5g/100ml
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Weiguang Biological
  • CTBB
  • Shanghai RAAS
  • Nanyue Biopharming
  • Hualan Bio
  • Sinopharm
  • Guangdong Shuagnlin Bio-pharmacy
  • Boya-Bio
  • Beijing Tiantan Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Dynamics
  1. 2.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends
  2. 2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers
  3. 2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges
  4. 2.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints
3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Manufacturers
  1. 3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers, Product Type & Application
  7. 3.7 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Tier 1, Tier 2, and Tier 3
4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Type
  1. 4.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Type Introduction
  2. 4.1.1 1.25g/25ml
  3. 4.1.2 10g/200ml
  4. 4.1.3 1g/20ml
  5. 4.1.4 2.5g/50ml
  6. 4.1.5 5g/100ml
  7. 4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type
  8. 4.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032)
  10. 4.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2032)
  11. 4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type
  12. 4.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032)
  14. 4.3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2032)
5 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Application
  1. 5.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application
  6. 5.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032)
  8. 5.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application
  10. 5.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032)
  12. 5.3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2032)
6 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region
  1. 6.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2032)
  3. 6.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026)
  4. 6.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region
  1. 7.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region
  2. 7.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032)
  8. 7.2.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032)
  11. 7.3.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Weiguang Biological
  2. 8.1.1 Weiguang Biological Company Information
  3. 8.1.2 Weiguang Biological Business Overview
  4. 8.1.3 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  6. 8.1.5 Weiguang Biological Recent Developments
  7. 8.2 CTBB
  8. 8.2.1 CTBB Company Information
  9. 8.2.2 CTBB Business Overview
  10. 8.2.3 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  12. 8.2.5 CTBB Recent Developments
  13. 8.3 Shanghai RAAS
  14. 8.3.1 Shanghai RAAS Company Information
  15. 8.3.2 Shanghai RAAS Business Overview
  16. 8.3.3 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  18. 8.3.5 Shanghai RAAS Recent Developments
  19. 8.4 Nanyue Biopharming
  20. 8.4.1 Nanyue Biopharming Company Information
  21. 8.4.2 Nanyue Biopharming Business Overview
  22. 8.4.3 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  24. 8.4.5 Nanyue Biopharming Recent Developments
  25. 8.5 Hualan Bio
  26. 8.5.1 Hualan Bio Company Information
  27. 8.5.2 Hualan Bio Business Overview
  28. 8.5.3 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  30. 8.5.5 Hualan Bio Recent Developments
  31. 8.6 Sinopharm
  32. 8.6.1 Sinopharm Company Information
  33. 8.6.2 Sinopharm Business Overview
  34. 8.6.3 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  36. 8.6.5 Sinopharm Recent Developments
  37. 8.7 Guangdong Shuagnlin Bio-pharmacy
  38. 8.7.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  39. 8.7.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  40. 8.7.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  42. 8.7.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  43. 8.8 Boya-Bio
  44. 8.8.1 Boya-Bio Company Information
  45. 8.8.2 Boya-Bio Business Overview
  46. 8.8.3 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  48. 8.8.5 Boya-Bio Recent Developments
  49. 8.9 Beijing Tiantan Biological Products
  50. 8.9.1 Beijing Tiantan Biological Products Company Information
  51. 8.9.2 Beijing Tiantan Biological Products Business Overview
  52. 8.9.3 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  54. 8.9.5 Beijing Tiantan Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Analysis
  2. 9.1.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process
  6. 9.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors
  9. 9.2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst